WEST LAFAYETTE, Ind. — Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback